Monoclonal Stem Cell Subfractionation for Atopic Dermatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining monoclonal mesenchymal stem cells for treating atopic dermatitis are inefficient, requiring numerous passages and high cell densities that lead to cell aging and reduced proliferation, making it difficult to achieve rapid and effective treatment.
Innovation Solution
An improved subfractionation culturing method that involves culturing bone marrow-derived cells at low densities (50-1000 cells/cm2) with antioxidants, reducing the number of passages needed and enhancing cell proliferation, resulting in a more effective treatment for atopic dermatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional subfractionation culturing methods are used to obtain monoclonal mesenchymal stem cells, then stem cells can be isolated and cultured, but numerous passages and high cell densities are required which lead to cell aging and reduced proliferation
Solution Approach 1:
The patent changes the cell density parameter from conventional high density to low density (50-1000 cells/cm²), and modifies the culture medium composition by adding specific antioxidants. These parameter changes enable rapid proliferation of monoclonal stem cells in fewer passages while maintaining cell quality and preventing aging, thus resolving the contradiction between isolation purity and time loss.
2Quantity of substance
If high cell densities are used in conventional culturing, then sufficient cell numbers can be obtained, but cell aging occurs and proliferation capacity is reduced
Solution Approach 1:
The patent inverts the conventional approach by using low cell density (50-1000 cells/cm²) instead of high density, combined with antioxidant-enriched culture medium. This parameter change enables obtaining sufficient cell quantities while maintaining high proliferation capacity and preventing cell aging, thus resolving the contradiction between quantity and reliability.
Solution Approach 2:
The patent introduces antioxidants as intermediary substances in the culture medium to protect stem cells from oxidative stress during low-density culturing. These antioxidants act as mediators that enable rapid proliferation while maintaining cell quality, resolving the contradiction between obtaining sufficient quantities and preserving proliferation capacity.
3Quantity of substance
If numerous passages are performed in conventional methods, then sufficient cell numbers can be achieved, but cell aging and reduced treatment effectiveness occur
Solution Approach 1:
By changing the cell density parameter to low density (50-1000 cells/cm²) and modifying culture conditions with antioxidants, the patent achieves sufficient cell quantities in fewer passages. This prevents cell aging and maintains high treatment effectiveness, resolving the contradiction between quantity and manufacturing precision.
Data Source
AI summary
Disclosed is a composition for prevention, treatment or ameliorating of atopic dermatitis, the composition containing a monoclonal stem cell obtained via improved subfractionation culturing of a stem cell, a preparation method thereof, and a method for treating atopic dermatitis using the same. According to the improved subfractionation culturing and proliferation method of the stem cell, a desired amount of the monoclonal stem cells may be obtained in a massive manner in a short time via the rapid proliferation of the monoclonal stem cell. The monoclonal mesenchymal stem cell as obtained has an enhanced effect of treatment, prevention or ameliorating of atopic dermatitis, and thus may be usefully used for an atopic dermatitis treatment agent.